| Baseline | 16 weeks therapy |
Nasal symptom score | | |
Placebo | 7.0 (1–12) | 7.0 (1–11) |
Omalizumab | 7.0 (3–10) | 0.5 (0–8)**,## |
Histamine increase ng·mL−1 | | |
Placebo | 0.58 (0.1–5.76) | 0.35 (0.01–4.39) |
Omalizumab | 1.17 (0.1–6.97) | 0.31 (0.01–1.58)* |
HSA increase mg·mL−1 | | |
Placebo | 8.22 (0.03–428.98) | 19.73 (0.01–107.78) |
Omalizumab | 15.30 (0.01–740.44) | 0.12 (0.01–6.38)**,## |